News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AllaChem Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection



8/5/2013 8:55:11 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

August 5, 2013 -- AllaChem, LLC announces the beginning of Phase I clinical studies of AV4025, a potent small molecule for the treatment of chronic hepatitis C infection. Hallandale Beach, Fl – July 25, 2013 - Alla Chem, LLC announced today the initiation of phase I clinical studies with AV4025, a next in-class small molecule HCV NS5A Inhibitor for the treatment of chronic hepatitis C infection. A double-blind, placebo-controlled, single ascending dose (10, 20 and 40 mg) study will evaluate safety, tolerability and pharmacokinetics of AV4025 upon oral administration in 30 healthy volunteers. The results of the pre-clinical and clinical studies will be presented at the 10th International Conference "Viral Hepatitis: Epidemiology, Diagnostics, Treatment and Prevention", September 17-19, 2013, Moscow, Russian Federation.

CONTACT:

Alena Ivachtchenko, MBA

Director Business Development

Phone: 1-858-35-6627

E-mail: alena.ivachtchenko@allachem.com; av@allachem.com

www.allachem.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
Alla Chem
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES